Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ales Kotalik

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Plos One|August 6, 2016
Do Your School Mates Influence How Long You Game? Evidence from the U.SAliaksandr Amialchuk, Ales Kotalik
Statistics in Medicine|November 10, 2021
A group-sequential randomized trial design utilizing supplemental trial dataAles Kotalik, David M Vock, Brian P Hobbs, et al.
Clinical Trials (London, England)|August 8, 2019
A win ratio approach to the re-analysis of Multiple Risk Factor Intervention TrialAles Kotalik, Anne Eaton, Qinshu Lian, et al.
Biostatistics (Oxford, England)|April 2, 2025
Within-trial data borrowing for sequential multiple assignment randomized trialsAles Kotalik, David M Vock, Nancy E Sherwood, et al.
Biostatistics (Oxford, England)|January 25, 2020
Dynamic borrowing in the presence of treatment effect heterogeneityAles Kotalik, David M Vock, Eric C Donny, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 10, 2024
Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATIONMichael E Wechsler, Daiana Stolz, Njira L Lugogo, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 2, 2024
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION studyChristopher E Brightling, Marco Caminati, Jean-Pierre Llanos, et al.
The Lancet. Respiratory Medicine|December 9, 2024
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trialDave Singh, Christopher E Brightling, Klaus F Rabe, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Plos One|August 6, 2016
Do Your School Mates Influence How Long You Game? Evidence from the U.SAliaksandr Amialchuk, Ales Kotalik
Statistics in Medicine|November 10, 2021
A group-sequential randomized trial design utilizing supplemental trial dataAles Kotalik, David M Vock, Brian P Hobbs, et al.
Clinical Trials (London, England)|August 8, 2019
A win ratio approach to the re-analysis of Multiple Risk Factor Intervention TrialAles Kotalik, Anne Eaton, Qinshu Lian, et al.
Biostatistics (Oxford, England)|April 2, 2025
Within-trial data borrowing for sequential multiple assignment randomized trialsAles Kotalik, David M Vock, Nancy E Sherwood, et al.
Biostatistics (Oxford, England)|January 25, 2020
Dynamic borrowing in the presence of treatment effect heterogeneityAles Kotalik, David M Vock, Eric C Donny, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 10, 2024
Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATIONMichael E Wechsler, Daiana Stolz, Njira L Lugogo, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 2, 2024
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION studyChristopher E Brightling, Marco Caminati, Jean-Pierre Llanos, et al.
The Lancet. Respiratory Medicine|December 9, 2024
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trialDave Singh, Christopher E Brightling, Klaus F Rabe, et al.
Pageof 1